Scancell shares healthy following patent approval award in Japan
Shares in cancer vaccine developer Scancell rose on Wednesday after the company announced its ImmunoBody Patent had been approved in Japan.
Shares in cancer vaccine developer Scancell rose on Wednesday after the company announced its ImmunoBody Patent had been approved in Japan.
The same patent has already been approved in the US, Europe and Australia.
Dr Richard Goodfellow, Joint Chief Executive Officer of Scancell, commented: "This is a further important step in the development and commercialisation of the ImmunoBody platform and provides further evidence to support the novelty of Scancell's ImmunoBody technology in another key pharmaceutical market.
"Scancell will continue building its growing portfolio of intellectual property in parralel with driving the clinical trial programme on SCIBI forward during 2013."
SCIBI is Scancell's first cancer vaccine which is currently being developed for the treatment of melanoma.
Scancell's share price was up 6.37% to 41.75p at 11:01 on Wednesday.
MF